|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3800 AUD | +2.70% |
|
+1.33% | -41.54% |
| 07-30 | Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy | MT |
| 07-21 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| Market Cap | 111M 77.78M 67.61M 62.93M 57.78M 109M 7.42B 742M 291M 3.7B 292M 286M 12.39B | P/E 2026 * |
-6.07x | P/E 2027 * | -4.35x |
|---|---|---|---|---|---|
| Enterprise Value | 116M 81.45M 70.81M 65.91M 60.51M 114M 7.78B 777M 305M 3.87B 306M 299M 12.98B | EV / Sales 2026 * |
14.9x | EV / Sales 2027 * | 10.9x |
| Free-Float |
60.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +2.70% | ||
| 1 week | +1.33% | ||
| Current month | +2.70% | ||
| 1 month | +1.33% | ||
| 3 months | -20.00% | ||
| 6 months | -36.67% | ||
| Current year | -41.54% |
| 1 week | 0.36 |  | 0.38 |
| 1 month | 0.35 | | 0.39 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.76 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/2/26 | Expiration | Chief Executive Officer | 2,250,000 | 0.7781% | ||
| 14/10/25 | Expiration | Chief Executive Officer | 745,962 | 0.3217% | ||
| 21/11/24 | Buy | Director | 1,000,000 | 0.4313% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.70% | +1.33% | +1.33% | -36.67% | 77.78M | |
| -0.53% | -3.95% | +50.70% | +152.78% | 1,024B | |
| +0.21% | -2.68% | +53.20% | +50.87% | 618B | |
| -2.51% | -3.25% | +28.54% | +67.99% | 443B | |
| +1.33% | -0.39% | +40.67% | +34.37% | 349B | |
| +0.26% | -1.32% | +34.09% | +42.40% | 297B | |
| -6.68% | -8.69% | +5.68% | +7.96% | 264B | |
| -0.08% | -6.20% | -2.16% | -42.94% | 209B | |
| -0.64% | +2.43% | +29.74% | +67.16% | 208B | |
| -0.82% | +0.70% | +15.05% | +72.05% | 162B | |
| Average | -0.67% | -0.93% | +25.68% | +41.60% | 357.38B | |
| Weighted average by Cap. | -0.84% | -2.17% | +36.78% | +73.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.78M 5.46M 4.75M 4.42M 4.06M 7.66M 521M 52.08M 20.44M 260M 20.51M 20.06M 870M | 12.5M 8.77M 7.62M 7.1M 6.52M 12.3M 837M 83.66M 32.83M 417M 32.94M 32.22M 1.4B |
| Net income | -18.29M -12.84M -11.16M -10.39M -9.54M -18.01M -1.23B -122M -48.06M -610M -48.22M -47.16M -2.05B | -25.1M -17.62M -15.32M -14.26M -13.09M -24.72M -1.68B -168M -65.95M -837M -66.17M -64.71M -2.81B |
| Net Debt | 5.24M 3.67M 3.19M 2.97M 2.73M 5.16M 351M 35.05M 13.76M 175M 13.8M 13.5M 586M | 24.96M 17.52M 15.23M 14.18M 13.02M 24.58M 1.67B 167M 65.59M 833M 65.81M 64.36M 2.79B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/08/26 | A$0.3800 | +2.70% | 120,803 |
| 31/07/26 | A$0.3700 | -1.33% | 29,912 |
| 30/07/26 | A$0.3750 | +2.74% | 55,543 |
| 29/07/26 | A$0.3650 | 0.00% | 35,714 |
| 28/07/26 | A$0.3650 | -2.67% | 34,989 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
